Alphatec Stock Discussion

$Alphatec (ATEC.US)$ will it rise again?

$Roblox (RBLX.US)$ $Anavex Life Sciences (AVXL.US)$ $Santech Holdings (STEC.US)$ $Lead Real Estate (LRE.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Carvana (CVNA.US)$ $Lemonade (LMND.US)$ $Autonomix Medical (AMIX.US)$ $Peloton Interactive (PTON.US)$ $PLBY Group (PLBY.US)$ $Alphatec (ATEC.US)$ $Universal Security Instruments (UUU.US)$ $Biofrontera (BFRI.US)$ $Root Inc (ROOT.US)$
🎃⚡️🎃

$Alphatec (ATEC.US)$ great solid takeoff

$Alphatec (ATEC.US)$ solid love it

$Sprouts Farmers Market (SFM.US)$ $J-Long Group (JL.US)$ $Confluent (CFLT.US)$ $Tenon Medical (TNON.US)$ $Adicet Bio (ACET.US)$ $Remitly Global (RELY.US)$ $Carvana (CVNA.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Alphatec (ATEC.US)$ $CPS Technologies (CPSH.US)$ $1847 Holdings (EFSH.US)$ $LuxUrban Hotels (LUXH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

$Gain Therapeutics (GANX.US)$ $Orion Group (ORN.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $1847 Holdings (EFSH.US)$ $Carvana (CVNA.US)$ $Junee (JUNE.US)$ $Tenon Medical (TNON.US)$ $Aditxt (ADTX.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

$Gelteq (GELS.US)$ $Etsy Inc (ETSY.US)$ $Orion Group (ORN.US)$ $Confluent (CFLT.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $Envista Holdings (NVST.US)$ $Carvana (CVNA.US)$ $1847 Holdings (EFSH.US)$ $Tenon Medical (TNON.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

$Alphatec (ATEC.US)$ Financial Outlook for the Full-Year 2024
For the fiscal year ended December 31, 2024, the Company now expects total revenue to grow 25% to $605 million compared to the previous expectation of $602 million. This includes surgical revenue of $540 million and EOS revenue of $65 million. The Company now expects non-GAAP adjusted EBITDA of approximately $27 million compared to the previous expectation of $25.5 million.

$Alphatec (ATEC.US)$
director purchase $283.50k (50k shares at $5.67) as stock hits a 52 week low
use risk management.

$Alphatec (ATEC.US)$
- Full year 2023 total revenue grew 37% to $482 million
- Full year 2023 adjusted EBITDA margin improved ~890 basis points
- Full year 2024 total revenue expected to approximate $595 million, enabling adjusted EBITDA margin expansion of approximately 560 basis points